


Gambogic amide

Cat. No.:	HY-121833												
CAS No.:	286935-60-2												
Molecular Formula:	C ₃₈ H ₄₅ NO ₇												
Molecular Weight:	627.77												
Target:	Trk Receptor; Akt; ERK												
Pathway:	Neuronal Signaling; Protein Tyrosine Kinase/RTK; PI3K/Akt/mTOR; MAPK/ERK Pathway; Stem Cell/Wnt												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



BIOLOGICAL ACTIVITY

Description	Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke ^[1] .								
In Vitro	<p>Gambogic amide (0.5 μM; 30 min) elicits TrkA tyrosine phosphorylation in hippocampal neurons^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Hippocampal neurons</td> </tr> <tr> <td>Concentration:</td> <td>500 nM</td> </tr> <tr> <td>Incubation Time:</td> <td>30 min</td> </tr> <tr> <td>Result:</td> <td>Triggered TrkA Y490 phosphorylation.</td> </tr> </table>	Cell Line:	Hippocampal neurons	Concentration:	500 nM	Incubation Time:	30 min	Result:	Triggered TrkA Y490 phosphorylation.
Cell Line:	Hippocampal neurons								
Concentration:	500 nM								
Incubation Time:	30 min								
Result:	Triggered TrkA Y490 phosphorylation.								
In Vivo	<p>Gambogic amide (2 mg/kg; sc; single dose) prevents neuronal cell death and decreases infarct volume in MCAO animal model^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>MCAO mice model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>s.c.; 5 min before the onset of reperfusion, after 2 h of MCAO followed by reperfusion; followed by 25 mg/kg Kainic acid (KA)</td> </tr> <tr> <td>Result:</td> <td>Diminished Kainic acid-triggered hippocampal neuronal cell death.</td> </tr> </table>	Animal Model:	MCAO mice model ^[1]	Dosage:	2 mg/kg	Administration:	s.c.; 5 min before the onset of reperfusion, after 2 h of MCAO followed by reperfusion; followed by 25 mg/kg Kainic acid (KA)	Result:	Diminished Kainic acid-triggered hippocampal neuronal cell death.
Animal Model:	MCAO mice model ^[1]								
Dosage:	2 mg/kg								
Administration:	s.c.; 5 min before the onset of reperfusion, after 2 h of MCAO followed by reperfusion; followed by 25 mg/kg Kainic acid (KA)								
Result:	Diminished Kainic acid-triggered hippocampal neuronal cell death.								



Reduces infarct volume in MCAO rat brain.

REFERENCES

[1]. Jang SW, et al. Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16329-34.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA